Contents
Download PDF
pdf Download XML
321 Views
140 Downloads
Share this article
Review Article | Volume 14 Issue:1 (Jan-Feb, 2024) | Pages 267 - 272
Looking Forward Vericiguat in Heart Failure - A Systematic Review
1
Professor and Head, Department of Medicine, MIMER Medical College, Talegaon Dabhade, Pune.
Under a Creative Commons license
Open Access
DOI : 10.5083/ejcm
Received
Nov. 15, 2023
Revised
Dec. 11, 2023
Accepted
Jan. 3, 2024
Published
Jan. 20, 2024
Abstract

Background:  Despite recent advances in heart failure (HF) management, mortality and morbidity remain high in patients with heart failure with reduced and preserved ejection fraction. HF is characterized by endothelial dysfunction, inflammation, and increased oxidative stress that results due to a reduction in the activity of the nitric oxide-soluble guanylate cyclase-cyclic guanosine monophosphate (NO-sGC-cGMP) signaling pathway. All these factors contribute to direct damage at the myocardial, vascular, and renal levels. At a fundamental level, it is known that this cardioprotective pathway of NO-sGC-cGMP is impaired in heart failure patients. Materials and Methods: Vericiguat is a soluble guanylate cyclase stimulator approved by various global regulatory bodies in January 2021 and recommended in recently updated clinical practice guidelines to reduce morbidity and mortality in patients with worsening chronic heart failure (HF) with reduced ejection fraction (HFrEF). It is a novel, orally used, small molecule, and direct stimulator of the soluble guanylate cyclase. It restores the deficiency in this signaling pathway, through stimulation and activation of sGC, aiming to increase cGMP levels, with a reduction in HF-related oxidative stress and endothelial dysfunction. For the present systematic review a Boolean search was carried out in Pubmed, Google Scholar and Embase. Conclusion: Overall, four main clinical trials have been carried out for vericiguat namely the SOCRATES-REDUCED, SOCRATES - PRESERVED, VICTORIA, and VITALITY. Vericiguat resulted in reduced CV death and HF hospitalization in patients with HFrEF and a recent episode of cardiac decompensation.

Keywords
Recommended Articles
Research Article
Battle of the Scores: SOFA v/s q SOFA in forecasting Critical Care Mortality
...
Published: 30/05/2025
Download PDF
Research Article
Imaging of Upper Airways for Pre-Anaesthetic Evaluation and Laryngeal Afflictions: An Original Research Study
Published: 30/05/2025
Download PDF
Research Article
Physiological Parameters in the Diagnosis and Management of Ocular Disorders
...
Published: 29/05/2025
Download PDF
Research Article
Evaluation of Focal Breast Lesions Using Ultrasound Elastography: An Original Research Study
Published: 30/05/2025
Download PDF
Chat on WhatsApp
Copyright © EJCM Publisher. All Rights Reserved.